Why did Abiomed stock drop 11% on Monday?
May 27, 2021 · ABMD stock is also up 49% from the levels of around $190 seen toward the end of 2017. The 49% rise over the last three years or so appears to be low, given the robust fundamentals of the company.
What is aBMD target price?
May 11, 2020 · The company's main products are the world's smallest heart pump, the Impella, and its supporting SmartAssist technology. Abiomed's share price vaulted up 31.8% in April, according to data provided ...
What drives Abiomed's Q2 earnings and revenue?
ABMD | Complete Abiomed Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
What is Abiomed’s (Abiomed) long-term growth rate?
Find the latest Abiomed, Inc. (ABMD) stock quote, history, news and other vital information to help you with your stock trading and investing.
Is ABMD stock a buy?
The Price to Earnings ratio or P/E is price divided by earnings....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy24.93%2Buy18.44%3Hold9.99%4Sell5.61%2 more rows
Why is Abmd going down?
Shares of Abiomed ( ABMD -2.85% ) closed down 10% today after the medical-device maker reported earnings from its second fiscal quarter and muted guidance for the quarter ahead due to the COVID-19 pandemic.Oct 29, 2020
What happened
So what
Abiomed ( NASDAQ:ABMD), the first company to implant a totally artificial heart in a patient back in 2001, develops technology to help hearts recover. The company's main products are the world's smallest heart pump, the Impella, and its supporting SmartAssist technology.
Now what
The financial results gave investors some much needed reassurance that Abiomed is not only surviving the health crisis, but continues to thrive.
Here's Why You Should Retain Abiomed (ABMD) Stock For Now
After a difficult year filled with safety concerns from the Food and Drug Administration and revenue misses, Abiomed is finally moving in the right direction. Now that the FDA has cleared the safety issues and the company registered good sales growth, Abiomed appears to have a brighter future.
Abiomed to Present at the SVB Leerink 11th Annual Global Healthcare Conference
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
Abiomed (ABMD) Beats on Q3 Earnings, Narrows FY22 Guidance
DANVERS, Mass., February 08, 2022--Abiomed to present at the SVB Leerink 11th Annual Global Healthcare conference.
Shares slump after a pair of clinical studies raises new questions about the safety and cost effectiveness of Abiomed's family of heart pumps. Here are the must-know details
Abiomed's (ABMD) strength in Impella product revenues drives its Q3 top line.
What happened
Brian Feroldi has been covering the healthcare and technology industries for The Motley Fool since 2015. Brian's investing strategy is to buy high-quality companies and then let compounding work its magic. See all of his articles here. Follow @brianferoldi
So what
Shares of Abiomed ( NASDAQ:ABMD) dropped about 11% as of 12:39 p.m. EST on Monday. The double-digit plunge is traceable to a pair of clinical studies that were presented over the weekend that raise new questions about the usefulness of the company's Impella heart pumps.
Now what
Two research teams presented data over the weekend at the American Heart Association's annual meeting in Philadelphia that questioned the safety and effectiveness of Abiomed's Impella heart pumps.
The medical-device maker misses Wall Street earnings estimates but continues to rack up impressive revenue growth
It's understandable that shares are falling in response to this news. If Impella truly isn't as clinically effective as the intra-aortic balloon, then Abiomed's revenue and profit will likely fall substantially.
What happened
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Follow @keithspeights
So what
Shares of Abiomed Inc. ( NASDAQ:ABMD) sank 11.3% as of 11:23 a.m. EDT on Thursday. The medical-device company, which primarily markets heart pumps, reported its fiscal year 2019 Q1 results before the market opened. The stock dropped in reaction to this update.
Now what
Is missing analysts' estimates by $0.04 a big deal? Not over the long run. In my view, today's decline is a result of a hypersensitive focus on the short term.
